TerThera B.V. is a Netherlands-based radionuclide production company founded in 2021, specializing in the development and supply of Terbium-161 (Tb-161) for nuclear medicine and radioligand therapy. The company focuses on establishing a reliable global supply of high-quality Tb-161 for clinical and research applications. TerThera produces no-carrier-added Terbium-161 and has introduced GMP-compliant Tb-161 for use in radiopharmaceutical development and patient treatment. Through dedicated production facilities and international partnerships, the company aims to expand access to this emerging therapeutic radionuclide while maintaining stringent quality and manufacturing standards.